The novel sirolimus-eluting ultra-high molecular weight 115-microns strut thickness APTITUDE® Bioreabsorbable vascular scaffold (BRS) (Amaranth Medical Inc., Mountain View, CA) displays higher mechanical strength, expansion capabilities and resistance to fracture compared to clinically available BRS technologies. RENASCENT II is a prospective, multi-center first-in-human clinical study to evaluate the clinical performance of the APTITUDE® BRS in the treatment of single de novo coronary lesions among patients undergoing percutaneous coronary intervention.
RENASCENT II: First in Human Evaluation of a Novel Sirolimus-Eluting Ultra-High Molecular Weight APTITUDE® Bioresorbable Scaffold: 9-and 24-Months Imaging and Clinical Results / Chieffo, Alaide; Khawaja, Saud Ahmed; Latib, Azeem; Vesga, Boris; Moncada, Miguel; Delgado, Juan A; Fonseca, Jaime; Testa, Luca; Esposito, Giovanni; Ferrone, Marco; Cortese, Bernardo; Maehara, Akiko; Granada, Juan F; Colombo, Antonio; Montorfano, Matteo; Hernandez, Hector; Arana, Camilo; Dager, Antonio; Bedogni, Francesco; Stabile, Eugenio; De Benedictis, Mauro; Meliga, Emanuele; Tarantini, Giuseppe; Antoniucci, David; La Manna, Alessio; Tamburino, Corrado. - In: EUROINTERVENTION. - ISSN 1969-6213. - 16:2(2020), pp. e133-e140. [10.4244/EIJ-D-19-00600]
RENASCENT II: First in Human Evaluation of a Novel Sirolimus-Eluting Ultra-High Molecular Weight APTITUDE® Bioresorbable Scaffold: 9-and 24-Months Imaging and Clinical Results
Esposito, Giovanni;Ferrone, Marco;Stabile, Eugenio;
2020
Abstract
The novel sirolimus-eluting ultra-high molecular weight 115-microns strut thickness APTITUDE® Bioreabsorbable vascular scaffold (BRS) (Amaranth Medical Inc., Mountain View, CA) displays higher mechanical strength, expansion capabilities and resistance to fracture compared to clinically available BRS technologies. RENASCENT II is a prospective, multi-center first-in-human clinical study to evaluate the clinical performance of the APTITUDE® BRS in the treatment of single de novo coronary lesions among patients undergoing percutaneous coronary intervention.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
